In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Glenmark gets rights to sell generic form of Nycomed's Cutivate

Executive Summary

Nycomed US Inc. (a division of Nycomed International Management GMBH) has entered into a royalty-bearing license agreement with Glenmark Pharmaceuticals Ltd.'s Glenmark Generics Ltd. to settle outstanding litigation. Nycomed had alleged that Glenmark’s ANDA for fluticasone 0.05% lotion infringed upon Nycomed's Cutivate for atopic dermatitis. Glenmark now has the right to sell its fluticasone lotion in March 2012; the company believes it will have 180 days of exclusivity since it will be the first generic on the market. Nycomed’s Cutivate had 2010 US sales of $48mm.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies